Role of tissue plasminogen activator in acute ischemic stroke

Annals of Pharmacotherapy

Volumn 45, Issue 3, 2011, Pages 364-371

  Hatcher, Molly A ^a   Starr, Jessica A ^b  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Alteplase; Cerebrovascular accident; Ischemic stroke; Thrombolytic; Tissue plasminogen activator

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG SAFETY; GLASGOW OUTCOME SCALE; HUMAN; MEDICAL SOCIETY; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANKIN SCALE; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; GUIDELINES AS TOPIC; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; PATIENT SELECTION; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79952663249     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P525     Document Type: Article

References (19)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181.
2. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for health care professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006;37:577-617.
3. Goldstein L, Appel L, Brass L, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006;37:1583-633.
4. Adams HP, Del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association. Stroke 2007;38:1655-711.
5. Albers GW, Amarenco P, Easton D, et al. Antithrombotic and thrombolytic therapy. Chest 2008;133:630S-69S.
6. Product information. Activase (alteplase). San Francisco, CA: Genentech, December 2005.
7. The National Institute of Neurological Disorders and Stroke rt-PA Stroke study group (NINDS). Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
8. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
9. Hacke W, Kaste M, Fieschi C, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet 1998;352:1245-51. (Pubitemid 28470336)
10. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000;31:811-6. (Pubitemid 30198420)
11. Clark WM, Wissman S, Alber GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - the ATLANTIS study: a randomized controlled trial. JAMA 1999;282:2019-26.
12. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
13. del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-8.
14. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703.
15. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-40.
16. Haley EC Jr, Levy DE, Brott TG, et al. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-5.
17. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet 2007;369:275-82. (Pubitemid 46138121)
18. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 hours after acute ischemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303-09.
19. Ahmed N, Wahlgren N, Grond M. Implementation and outcome of thrombolysis with alteplase 3- 4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology 2010;9:866-874.